CytomX Therapeutics Inc
CTMX4.400USD
+0.200+4.76%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
726.31MMarket Cap
14.94P/E TTM
More Details of CytomX Therapeutics Inc Company
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
CytomX Therapeutics Inc Info
Ticker SymbolCTMX
Company nameCytomX Therapeutics Inc
IPO dateOct 08, 2015
CEOMccarthy (Sean A)
Number of employees119
Security typeOrdinary Share
Fiscal year-endOct 08
Address151 Oyster Point Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16505153185
Websitehttps://cytomx.com/
Ticker SymbolCTMX
IPO dateOct 08, 2015
CEOMccarthy (Sean A)
Company Executives of CytomX Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
5.14K
--
Dr. Yu-Waye (Wayne) Chu, M.D.
Dr. Yu-Waye (Wayne) Chu, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
4.72K
-96.52%
Mr. Chris Ogden
Mr. Chris Ogden
Senior Vice President, Chief Financial Officer, Assistant Secretary
Senior Vice President, Chief Financial Officer, Assistant Secretary
--
--
Ms. Halley Gilbert
Ms. Halley Gilbert
Independent Director
Independent Director
--
--
Dr. Zhen Su, M.D.
Dr. Zhen Su, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew P. (Matt) Young
Mr. Matthew P. (Matt) Young
Lead Independent Director
Lead Independent Director
--
--
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alan Ashworth, Ph.D.
Dr. Alan Ashworth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Robert (Jim) Meyers
Mr. James Robert (Jim) Meyers
Independent Director
Independent Director
--
--
Dr. Sean A. Mccarthy, Ph.D.
Dr. Sean A. Mccarthy, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
5.14K
--
Dr. Yu-Waye (Wayne) Chu, M.D.
Dr. Yu-Waye (Wayne) Chu, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
4.72K
-96.52%
Mr. Chris Ogden
Mr. Chris Ogden
Senior Vice President, Chief Financial Officer, Assistant Secretary
Senior Vice President, Chief Financial Officer, Assistant Secretary
--
--
Ms. Halley Gilbert
Ms. Halley Gilbert
Independent Director
Independent Director
--
--
Dr. Zhen Su, M.D.
Dr. Zhen Su, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew P. (Matt) Young
Mr. Matthew P. (Matt) Young
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
50.92M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
VR Adviser, LLC
9.18%
Fidelity Management & Research Company LLC
7.72%
Longitude Capital Management Co., LLC
6.81%
Tang Capital Management, LLC
6.53%
Perceptive Advisors LLC
5.71%
Other
64.05%
Shareholders
Shareholders
Proportion
VR Adviser, LLC
9.18%
Fidelity Management & Research Company LLC
7.72%
Longitude Capital Management Co., LLC
6.81%
Tang Capital Management, LLC
6.53%
Perceptive Advisors LLC
5.71%
Other
64.05%
Shareholder Types
Shareholders
Proportion
Hedge Fund
31.55%
Venture Capital
19.28%
Investment Advisor
19.07%
Private Equity
10.71%
Investment Advisor/Hedge Fund
6.58%
Research Firm
1.31%
Individual Investor
0.57%
Pension Fund
0.14%
Corporation
0.03%
Other
10.77%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
207
150.19M
97.87%
--
2025Q3
210
150.19M
100.73%
+1.02M
2025Q2
183
145.99M
57.70%
+76.42M
2025Q1
172
46.18M
92.00%
-27.51M
2024Q4
180
47.66M
94.88%
-4.47M
2024Q3
185
52.13M
91.84%
-5.46M
2024Q2
195
57.58M
79.01%
+7.29M
2024Q1
230
45.58M
81.93%
-10.24M
2023Q4
237
33.73M
89.70%
+246.26K
2023Q3
267
33.75M
106.91%
-1.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
VR Adviser, LLC
13.97M
8.47%
+977.38K
+7.52%
Jun 30, 2025
Fidelity Management & Research Company LLC
8.66M
5.25%
+8.55M
+7898.03%
Jun 30, 2025
Longitude Capital Management Co., LLC
11.54M
7%
+11.54M
--
May 13, 2025
Tang Capital Management, LLC
11.07M
6.71%
+4.35M
+64.72%
Jun 30, 2025
Perceptive Advisors LLC
9.68M
5.87%
+2.69M
+38.41%
Aug 14, 2025
The Vanguard Group, Inc.
9.38M
5.69%
+4.26M
+83.29%
Jun 30, 2025
OrbiMed Advisors, LLC
8.46M
5.13%
+8.46M
--
Jun 30, 2025
Commodore Capital LP
7.69M
4.66%
+7.69M
--
Jun 30, 2025
Baker Bros. Advisors LP
3.48M
2.11%
+3.48M
--
Jun 30, 2025
Point72 Asset Management, L.P.
8.08M
4.9%
-5.01M
-38.26%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Inspire Fidelis Multi Factor ETF
1.8%
Formidable ETF
1.75%
Invesco NASDAQ Future Gen 200 ETF
0.94%
First Trust Dow Jones Select MicroCap Index Fund
0.72%
Fidelity Fundamental Small-Mid Cap ETF
0.1%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Dimensional US Core Equity 1 ETF
0%
Inspire Fidelis Multi Factor ETF
Proportion1.8%
Formidable ETF
Proportion1.75%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.94%
First Trust Dow Jones Select MicroCap Index Fund
Proportion0.72%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.1%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of CytomX Therapeutics Inc?
The top five shareholders of CytomX Therapeutics Inc are:
VR Adviser, LLC holds 13.97M shares, accounting for 8.47% of the total shares.
Fidelity Management & Research Company LLC holds 8.66M shares, accounting for 5.25% of the total shares.
Longitude Capital Management Co., LLC holds 11.54M shares, accounting for 7.00% of the total shares.
Tang Capital Management, LLC holds 11.07M shares, accounting for 6.71% of the total shares.
Perceptive Advisors LLC holds 9.68M shares, accounting for 5.87% of the total shares.
VR Adviser, LLC holds 13.97M shares, accounting for 8.47% of the total shares.
Fidelity Management & Research Company LLC holds 8.66M shares, accounting for 5.25% of the total shares.
Longitude Capital Management Co., LLC holds 11.54M shares, accounting for 7.00% of the total shares.
Tang Capital Management, LLC holds 11.07M shares, accounting for 6.71% of the total shares.
Perceptive Advisors LLC holds 9.68M shares, accounting for 5.87% of the total shares.
What are the top three shareholder types of CytomX Therapeutics Inc?
The top three shareholder types of CytomX Therapeutics Inc are:
VR Adviser, LLC
Fidelity Management & Research Company LLC
Longitude Capital Management Co., LLC
VR Adviser, LLC
Fidelity Management & Research Company LLC
Longitude Capital Management Co., LLC
How many institutions hold shares of CytomX Therapeutics Inc (CTMX)?
As of 2025Q4, 207 institutions hold shares of CytomX Therapeutics Inc, with a combined market value of approximately 150.19M, accounting for 97.87% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.85%.
What is the biggest source of revenue for CytomX Therapeutics Inc?
In FY2025Q1, the -- business generated the highest revenue for CytomX Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
